These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23907046)

  • 1. Elevated urea level is associated with poor clinical outcome and increased mortality post intravenous tissue plasminogen activator in stroke patients.
    Zhang Y; Churilov L; Meretoja A; Teo S; Davis SM; Yan B
    J Neurol Sci; 2013 Sep; 332(1-2):110-5. PubMed ID: 23907046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
    Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure variability after intravenous thrombolysis in acute stroke does not predict intracerebral hemorrhage but poor outcome.
    Kellert L; Sykora M; Gumbinger C; Herrmann O; Ringleb PA
    Cerebrovasc Dis; 2012; 33(2):135-40. PubMed ID: 22179586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
    Huang YH; Zhuo ST; Chen YF; Li MM; Lin YY; Yang ML; Chen ZJ; Cai RW
    Chin Med J (Engl); 2013; 126(24):4685-90. PubMed ID: 24342312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-hospital outcomes with thrombolytic therapy in patients with renal dysfunction presenting with acute ischaemic stroke.
    Agrawal V; Rai B; Fellows J; McCullough PA
    Nephrol Dial Transplant; 2010 Apr; 25(4):1150-7. PubMed ID: 19945951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke mimics treated with thrombolysis: further evidence on safety and distinctive clinical features.
    Guillan M; Alonso-Canovas A; Gonzalez-Valcarcel J; Garcia Barragan N; Garcia Caldentey J; Hernandez-Medrano I; Defelipe-Mimbrera A; Sanchez-Gonzalez V; Terecoasa E; Alonso de Leciñana M; Masjuan J
    Cerebrovasc Dis; 2012; 34(2):115-20. PubMed ID: 22854315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy.
    Masrur S; Abdullah AR; Smith EE; Hidalgo R; El-Ghandour A; Rordorf G; Schwamm LH
    J Stroke Cerebrovasc Dis; 2011; 20(2):124-30. PubMed ID: 20598579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants.
    Matute MC; Masjuan J; Egido JA; Fuentes B; Simal P; Díaz-Otero F; Reig G; Díez-Tejedor E; Gil-Nuñez A; Vivancos J; Alonso de Leciñana M
    Cerebrovasc Dis; 2012; 33(3):231-9. PubMed ID: 22261670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
    Saposnik G; Demchuk A; Tu JV; Johnston SC;
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):876-82. PubMed ID: 23102741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between renal function and clinical outcome in patients with acute stroke.
    Hao Z; Wu B; Lin S; Kong FY; Tao WD; Wang DR; Liu M
    Eur Neurol; 2010; 63(4):237-42. PubMed ID: 20332640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study.
    Paciaroni M; Agnelli G; Caso V; Pieroni A; Bovi P; Cappellari M; Zini A; Nichelli P; Inzitari D; Nesi M; Nencini P; Pezzini A; Padovani A; Tassinari T; Orlandi G; Chiti A; Gialdini G; Alberti A; Venti M; Acciarresi M; D'Amore C; Luda E; Tassi R; Martini G; Ferrarese C; Beretta S; Trentini C; Silvestrelli G; Lanari A; Previdi P; Ciccone A; Delodovici ML; Bono G; Galletti G; Marcheselli S; Del Sette M; Traverso E; Riva M; Silvestrini M; Cerqua R; Consoli D; Monaco S; Toni D
    Cerebrovasc Dis; 2012; 34(5-6):430-5. PubMed ID: 23207482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
    Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
    J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis.
    Sobesky J; Frackowiak M; Zaro Weber O; Hahn M; Möller-Hartmann W; Rudolf J; Neveling M; Grond M; Schmulling S; Jacobs A; Heiss WD
    Cerebrovasc Dis; 2007; 24(1):56-65. PubMed ID: 17519545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
    Wahlgren N; Ahmed N; Dávalos A; Hacke W; Millán M; Muir K; Roine RO; Toni D; Lees KR;
    Lancet; 2008 Oct; 372(9646):1303-9. PubMed ID: 18790527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is renal dysfunction associated with adverse stroke outcome after thrombolytic therapy?
    Hsieh CY; Lin HJ; Sung SF; Hsieh HC; Lai EC; Chen CH
    Cerebrovasc Dis; 2014; 37(1):51-6. PubMed ID: 24401854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Syndrome Predicts Refractoriness to Intravenous Thrombolysis in Acute Ischemic Stroke.
    Dorado L; Arenillas JF; López-Cancio E; Hernández-Pérez M; Pérez de la Ossa N; Gomis M; Millán M; Granada ML; Galán A; Palomeras E; Dávalos A
    J Stroke Cerebrovasc Dis; 2015 Nov; 24(11):2605-12. PubMed ID: 26363707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.